Here, we correlated aberrant FAT1 expression in T-ALL with promotor hypomethylation and discovered increased FAT1 expression by drug treatment with the hypomethylating agents Decitabine or 5-Azacytidine. Here, FAT1 is linked to acute lymphoblastic leukemia.